枸橼酸与肝素抗凝对脓毒性休克患儿连续血液净化的凝血功能及疗效比较研究
本研究为病例对照研究,纳入2019年7月至2022年9月赣南医学院第一附属医院PICU收治的37例脓毒性休克行连续血液净化(CBP)的患儿,按抗凝方式分为枸橼酸局部抗凝组(17例)和肝素全身抗凝组(20例)。比较治疗前及停CBP后1天的凝血指标、炎症介质、CBP期间出血并发症及7天病死率。结果显示两组炎症介质均较治疗前显著下降(均P<0.05),组间无显著差异(均P>0.05);肝素组PT缩短、D-二聚体降低较枸橼酸组更明显(P<0.05,P<0.01);两组出血并发症(5.9% vs 30.0%)及7天病死率(17.6% vs 20.0%)无显著差异(均P>0.05)。作者认为肝素全身抗凝可能有利于防治DIC。
要点
- 脓毒性休克患儿CBP后1天,肝素全身抗凝组PT较枸橼酸局部抗凝组显著缩短(s:11.82±2.05 vs. 13.61±3.05,P<0.05)。
- 肝素组D-二聚体较枸橼酸组显著降低(mg/L:1.92±1.58 vs. 3.77±2.38,P<0.01),作者认为可能有利于防治DIC。
- 两组炎症介质(hs-CRP、PCT、IL-6、TNF-α)均较治疗前显著下降(均P<0.05),但组间比较无显著差异(均P>0.05)。
- CBP期间出血并发症枸橼酸组5.9% vs 肝素组30.0%,7天病死率17.6% vs 20.0%,均无显著差异(均P>0.05)。
适用人群与场景
- 2019年7月至2022年9月赣南医学院第一附属医院PICU收治的脓毒性休克行连续血液净化(CBP)的患儿37例,按抗凝方式分为枸橼酸局部抗凝组17例和肝素全身抗凝组20例。
研究设计与关键结果
- 研究类型:病例对照研究;样本量37例(枸橼酸局部抗凝组17例,肝素全身抗凝组20例);人群:脓毒性休克行CBP的患儿;干预与对照:枸橼酸局部抗凝 vs 肝素全身抗凝。
- 两组性别、年龄、体重等一般资料及治疗前凝血指标、炎症介质基线水平均无统计学显著差异。
- 停CBP后1天,肝素组PT较治疗前显著缩短(s:11.82±2.05 vs. 13.64±2.54),APTT和TT显著延长[APTT(s):51.54±12.69 vs. 35.53±10.79,TT(s):21.95±4.74 vs. 19.30±3.33],D-二聚体显著降低(mg/L:1.92±1.58 vs. 4.94±3.94),差异均有统计学意义(均P<0.05)。
- 枸橼酸组停CBP后1天仅APTT较治疗前显著延长(s:49.28±10.32 vs. 34.34±10.32,P<0.05),其余凝血指标与治疗前比较无统计学显著差异。
- 停CBP后1天组间比较:肝素组PT较枸橼酸组显著缩短(s:11.82±2.05 vs. 13.61±3.05,P<0.05),D-二聚体显著降低(mg/L:1.92±1.58 vs. 3.77±2.38,P<0.01)。
- 停CBP后1天两组炎症介质均较治疗前显著下降(均P<0.05):枸橼酸组hs-CRP(mg/L)12.53±5.44 vs. 22.65±7.27、PCT(μg/L)1.86±1.20 vs. 3.30±2.34、IL-6(ng/L)148.48±34.83 vs. 202.32±48.62、TNF-α(ng/L)21.38±7.71 vs. 55.14±15.07;肝素组hs-CRP(mg/L)11.82±4.93 vs. 21.62±8.35、PCT(μg/L)1.90±1.08 vs. 3.18±1.97、IL-6(ng/L)143.81±33.41 vs. 194.02±46.89、TNF-α(ng/L)22.44±8.17 vs. 56.17±16.92。
- 两组炎症介质停CBP后1天组间比较均无统计学显著差异(均P>0.05)。
- CBP期间出血并发症枸橼酸组5.9% vs 肝素组30.0%,7天病死率17.6% vs 20.0%,组间均无统计学显著差异(均P>0.05)。
证据类型、等级与局限
- 证据类型:病例对照研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,肝素全身抗凝与枸橼酸局部抗凝均可显著降低脓毒性休克患儿IL-6、TNF-α、hs-CRP和PCT水平,减轻炎症风暴。
- 作者认为,与枸橼酸局部抗凝相比,肝素全身抗凝可缩短脓毒性休克患儿PT并降低D-二聚体水平,可能有利于防治弥散性血管内凝血(DIC)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To compare the effects of citrate and heparin anticoagulation on coagulation function and efficacy in children with septic shock undergoing continuous blood purification (CBP), and to provide guidance for CBP anticoagulation in children with septic shock.
METHODS: A case control study was conducted. Thirty-seven children with septic shock admitted to the pediatric intensive care unit (PICU) of the First Affiliated Hospital of Gannan Medical University from July 2019 to September 2022 were enrolled as the research subjects. The patients were divided into citrate local anticoagulation group and heparin systemic anticoagulation group according to different anticoagulation methods. The baseline data, the level of coagulation indicators [prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (Fib), D-dimer] before treatment and 1 day after weaning from CBP, serum inflammatory mediators [interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), hypersensitivity C-reactive protein (hs-CRP), procalcitonin (PCT)], bleeding complications during CBP and 7-day mortality were collected.
RESULTS: A total of 37 cases were enrolled finally, including 17 cases with citric acid local anticoagulation and 20 cases with heparin systemic anticoagulation. There was no statistically significant difference in general data such as gender, age, and body weight of children between the two groups. There were no statistically significant differences in baseline levels of coagulation indicators and inflammatory mediators before treatment of children between the two groups. One day after weaning from CBP, both groups showed varying degrees of improvement in coagulation indicators compared with those before treatment. Compared with before treatment, the PT of the heparin systemic anticoagulation group was significantly shortened after 1 day of weaning (s: 11.82±2.05 vs. 13.64±2.54), APTT and TT were significantly prolonged [APTT (s): 51.54±12.69 vs. 35.53±10.79, TT (s): 21.95±4.74 vs. 19.30±3.33], D-dimer level was significantly reduced (mg/L: 1.92±1.58 vs. 4.94±3.94), with statistically significant differences (all P < 0.05). While in the citrate local anticoagulation group, only APTT was significantly prolonged after treatment compared with that before treatment (s: 49.28±10.32 vs. 34.34±10.32, P < 0.05). There were no statistically significant differences in other coagulation indicators compared with before treatment. Compared with the citric acid local anticoagulation group, the PT of the heparin systemic anticoagulation group was significantly shortened after treatment (s: 11.82±2.05 vs. 13.61±3.05, P < 0.05), and the D-dimer level was significantly reduced (mg/L: 1.92±1.58 vs. 3.77±2.38, P < 0.01). The levels of inflammatory mediators in both groups were significantly reduced 1 day after CBP weaning compared with those before treatment [citric acid local anticoagulation group: hs-CRP (mg/L) was 12.53±5.44 vs. 22.65±7.27, PCT (μg/L) was 1.86±1.20 vs. 3.30±2.34, IL-6 (ng/L) was 148.48±34.83 vs. 202.32±48.62, TNF-α (ng/L) was 21.38±7.71 vs. 55.14±15.07; heparin systemic anticoagulation group: hs-CRP (mg/L) was 11.82±4.93 vs. 21.62±8.35, PCT (μg/L) was 1.90±1.08 vs. 3.18±1.97, IL-6 (ng/L) was 143.81±33.41 vs. 194.02±46.89, TNF-α (ng/L) was 22.44±8.17 vs. 56.17±16.92, all P < 0.05]. However, there was no statistically significant difference between the two groups (all P > 0.05). There was no statistically significant difference in bleeding complication during CBP and 7-day mortality in children between the citrate local anticoagulation group and the heparin systemic anticoagulation group (5.9% vs. 30.0%, 17.6% vs. 20.0%, both P > 0.05).
CONCLUSIONS: Heparin for systemic anticoagulation and regional citrate anticoagulation can significantly reduce the levels of IL-6, TNF-α, hs-CRP and PCT in children with septic shock, and relieve inflammatory storm. Compared with citric acid local anticoagulation, heparin systemic anticoagulation can shorten the PT and reduce the level of D-dimer in children with septic shock, which may benefit in the prevention and treatment of disseminated intravascular coagulation (DIC).
参考来源
- Zhong X, Luo S, Ren R, et al. [A comparative study of the effects of citrate and heparin anticoagulation on coagulation function and efficacy in children with septic shock undergoing continuous blood purification]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2023. PMID: 37593866. doi:10.3760/cma.j.cn121430-20221108-00974
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。